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Introduction
Myotonic Dystrophy type 2 (DM2), or Proximal Myotonic 
Myopathy (PROMM), is a late-onset inherited and progressive muscular 
dystrophy with multi-system manifestations [1-5]. The etiology of DM2 
is traced to a tetranucleotide (CCTG) repeat expansion located on the 
CNBP gene resulting in abnormal cardiac and skeletal muscle function 
[6-9]. Despite having similar features to Myotonic Dystrophy type 1 
(DM1), DM2 is clinically distinct, originating from a different gene 
locus [1,2,4,10]. DM2 is characterized by a milder clinical presentation, 
later onset of symptoms, and more proximal versus distal weakness 
[4,5,9,11]. Other clinical features include somnolence, weakness, muscle 
pain and stiffness, cramping and fatigue, which impact quality of life 
[1,6,8]. Compared to DM1, DM2 is less severe and the exact prevalence 
is a topic of ongoing study [7-9,12]. 
Similar to DM1, a hallmark feature of DM2 is myotonia [6-8]. Grip 
myotonia is often the first symptom experienced with noticeable delay 
in the relaxation of the long finger flexors [6,8]. Myotonia may also be 
noted in the calf musculature or in the thumb. DM2 selectively affects 
the neck flexors, long finger flexors, elbow extensors, and proximal 
girdle musculature [1,6,8]. Hip flexor and extensor weakness can 
disrupt functional mobility, particularly during ambulation and stair 
climbing [3,5-8,11]. Persons with DM2 may vary in the degree to which 
the disease impacts functional mobility [6]. Therefore, any number of 
physical performance or functional outcome measures may be selected 
to monitor change or response to treatment. However, there are few 
published studies that have utilized functional outcome measures in the 
assessment of persons with DM2. 
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Abstract
Myotonic dystrophy type 2 (DM2) is a progressive muscular dystrophy with multi-system manifestations and can affect functional mobility, gait, 
and balance. Currently, there are few reports of functional outcome measures in this population. This case describes the change in function detected 
by the High-level Mobility Assessment Tool (HiMAT) and 30-second Chair Stand Test (CST) in a high-functioning adult female with DM2 after 
physical therapy treatment. The patient’s chief complaint was muscular pain and fatigue that affected activities of daily living (ADLs). Multi-
modal physical therapy focused on neuromuscular re-education, balance and strength training, patient education, and moderate cardiorespiratory 
training. Improvements were observed in manual muscle testing and in single-limb standing balance. A nine-point total improvement was observed 
in HiMAT score, and the CST detected a 100% improvement in number of sit-to-stands. The patient returned to prior level of function and was able 
to resume ADLs and recreational activities without complaints of muscular pain or fatigue.
The High-level Mobility Assessment Tool (HiMAT) appears to 
be an appropriate measure of functional mobility for persons with 
DM2. The HiMAT has previously demonstrated sound psychometric 
properties and has been normative referenced in healthy subjects [13-
19]. These properties have led to the application of the HiMAT as a 
valid and reliable measurement tool in the outpatient rehabilitation 
of persons with other neurological disorders. Furthermore, repetitive 
sit-to-stand testing is frequently used as an indicator of functional 
strength in the lower extremities and has been widely studied across 
populations [20-23]. However, to date, there have been no published 
reports examining the use of either the HiMAT or the 30-sec Chair 
Stand Test (CST) in persons with DM2. Therefore, the purpose of this 
case report is to describe the use of the HiMAT and CST in a patient 




An ambulatory 46-year-old Caucasian female, referred to as Jane 
Doe (J.D.) and diagnosed with DM2 by a neurologist at age 33 years, 
presented to an outpatient PT clinic with no apparent functional 
limitations.  J.D. reported independence with all functional Activities of 
Daily Living (ADLs).  J.D is a stay-at-home mother of three school-aged 
children. A typical daily schedule consists of moderate physical activity 
demands during meal preparation, basic and heavy-duty housekeeping 
(cleaning/laundry), driving, shopping and running errands.  The chief 
complaint was muscle pain and weakness during prolonged activity, 
especially squatting and walking, with an overall goal to restore 
strength and return to running and gym-based exercises.  J.D. reported 
experiencing pain (5/10 at worst) in her legs and difficulty with sit-to-
stand activities.  J.D. had been unable to participate in normal exercise 
for the prior six months due to disease-related symptoms. Written 
informed consent was obtained prior to treatment, as well as for 
inclusion in this case report. 
Abbreviations: ADLs – activities of daily living; CCTG – tetranucleotide (cytosine-cytosine-thymine-guanine) expansion; DM1 – myotonic 
dystrophy type 1; DM2 – myotonic dystrophy type 2; J.D. – patient pseudonym (Jane Doe); LE – lower extremity; LLE – left lower extremity; LOB 
– loss of balance; MMT – manual muscle testing; PROMM – proximal myotonic myopathy; PT – physical therapy / physical therapist; RLE – right 
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Examination
Upon PT examination, a standing postural assessment revealed 
lumbar hyperlordosis and knee hyperextension. A slight resting tremor 
was noted bilaterally in the upper and lower extremities. No deficits 
in active or passive range of motion were found in the upper or lower 
extremities. Isometric break testing revealed grossly normal strength 
for bilateral upper extremities. Manual Muscle Testing (MMT) was 
performed more extensively in the lower extremities and results can be 
found in Table 1.  MMT was performed according to procedures and 
positions outlined by Kendall FP et al. [24] Proximal muscle weakness 
was noted in the hip and knee joints with the left side being slightly 
more affected. Ankle dorsiflexion strength was found to be within 
normal limits. Ankle plantarflexion strength was tested using the 
multiple heel-rise in standing with no deficits. However, a prolonged 
lowering time after heel-rise was observed indicating a delayed muscle 
relaxation consistent with myotonia. Observational gait analysis 
revealed independent ambulation and a normal reciprocal pattern 
without noticeable deviations. J.D. could successfully ascend and 
descend a flight of stairs using a reciprocal pattern without the use of 
upper extremity support but was slower and appeared cautious. 
Outcome Measures
High-level Mobility Assessment Tool (HiMAT):  The HiMAT was 
selected to assess the response to more challenging mobility demands 
in this case. The HiMAT was originally developed to assess balance in 
high-functioning survivors of traumatic brain injury to quantify the 
need for assistance with functional mobility [13-19]. The tool requires 
that participants be able to ambulate at least 20-meters without assistive 
devices or orthoses [13]. The HiMAT contains multiple test items, 
including: walking, running, skipping, hopping, bounding, jumping, 
and stair negotiation [13-15]. Participants complete each item at 
the safest maximum speed possible [13-15]. The test is hierarchical 
in nature and consists of thirteen total items based upon a five-point 
scale, where higher scores equate to increasing performance, as seen 
in Table 2. Normative values of the HiMAT have been established for 
healthy young adults (ages 18-25 years) with high test-retest reliability 
(ICC=0.88, 95% CI 0.82-0.92) [13,18]. The HiMAT has demonstrated 
great psychometric properties including external concurrent validity, 
excellent reliability [0.88-0.99], high internal consistency [0.91-0.95], 
and low standard error of measurement (SEM)[0.79-1.36] [16-19]. 
Chair Stand Test (CST)
Functional strength of the lower extremities was assessed using 
the CST [20]. This test was selected as it requires repetitive movement 
using proximal musculature over 30 seconds. This test allows for the 
observation of the effects of proximal weakness or the prolonged muscle 
relaxation characteristic of DM2 on functional mobility. Strong test-
retest reliability and validity of the CST have been found in healthy 
community-dwelling adults, among other populations [20-25]. This test 
was performed in accordance with prior studies [20-25]. 
Standing Balance Assessment
Clinical balance assessment was performed using the single- and 
double-limb standing balance test with eyes-opened or eyes-closed on 
a firm surface. This test was performed in accordance with prior studies 
and occurred over 30 seconds in each position [26]. 
Treatment
J.D. received PT treatment once a week for eight consecutive weeks. 
The goals of PT intervention were to: 
1.) Return to prior levels of daily function and physical activity without 
onset of fatigue, pain, or weakness; 
2.) Return to a gym-based fitness program and recreational running; 
and 
3.) Restore quality of life.  
PT interventions included light to moderate resistance training 
of the pelvic and shoulder girdle muscles and neuromuscular re-
education techniques concentrating on improving motor and postural 
control to prevent movement compensations. Postural stabilization 
techniques in developmental positions such as high kneeling and 
quadruped were utilized. Tactile and verbal cueing was utilized to 
correct movement dysfunction during treatment sessions. Single limb 
stance balance training, reciprocal movement coordination training, 
and cardiorespiratory conditioning were also employed. For this case, 
submaximal cardiorespiratory training was performed at a light-
moderate intensity (40-60% of HRR) and slowly progressed as tolerated 
[27] The Borg rate of perceived exertion (RPE) (6-20) was used to 
monitor patient effort during all activities. Patient education stressed 
complete muscle relaxation between repetitions and limited repetitions 
based upon movement quality. A key component of the treatment plan 
included tracking the response to treatment to allow for the optimal 
modification and progression of exercise dose and intensity. Therefore, 
J.D. kept a daily log of activities and recorded muscle pain, weakness, 
fatigue and functional decline. Each treatment session began with an 
activity log review and served as the basis to progress or modify the PT 
treatment plan. A summary of the patient activity log (response to prior 
treatment), clinical reasoning, and intervention for each PT visit can be 
found in Supplemental Table 1.
Results
At the completion of eight weeks in PT, strength, single-limb 
standing balance, and functional performance improved. Results of 
MMT can be found in Table 1. Hip and knee strength improved on Table 1:  Results of Manual Muscle Testing.
Muscle / Muscle Group (test position)
Initial Evaluation Week 4 Re-evaluation Week 8 Re-evaluation prior to d/c
Right Left Right Left Right Left
Hip Flexors (seated) 4+/5 4+/5 4+/5 4+/5 4+/5 4/5
Hip Abductors (side lying) 4+/5 4/5 4+/5 4/5 5/5 4+/5
Hip Adductors (side lying) 4+/5 4/5 4+/5 4/5 5/5 5/5
Gluteus Maximus
(prone-knee flexed to 90deg.) 3+/4 3/5 4/5 4/5 4+/5 4/5
Biceps Femoris
(prone-knee extended) 3+/5 4/5 4+/5 4+/5 5/5 4+/5
Knee Flexors (prone) 3+/5 3/5 5/5 4+/5 5/5 4+/5
Knee Extensors (seated) 3+/5 3/5 4+/5 4+/5 5/5 5/5
*Manual muscle testing (MMT) grading scale according to Kendall & McCreary, Muscles: Testing and Function (1983)
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MMT.  J.D. returned to exercising 4-5 times/week alternating between 
the gym, running, and a home exercise program. Single-limb balance 
eyes-open on a firm surface improved from 25 sec (LLE) and 30 sec 
(RLE) to 60 sec bilaterally; single limb balance eyes-closed on a firm 
surface improved from inability to perform (0.0 sec) (bilaterally) to 
17.29 sec on RLE and to 5.65 sec on LLE.
Results for the HiMAT can be found in Table 2. On initial 
examination J.D. scored 38/54 and fell below the normative value range 
of 44-54 for a healthy adult female aged 18-25 [13,15-17,19]. At week 
5, her score on the HiMAT improved by 15% to a 46/54. The HiMAT 
score was stable between week five and the final visit. Initially, J.D. 
completed 10 stands in the allotted 30-seconds of the CST and scored 
15%ile, equivalent for a woman aged 60-64 years [20]. Upon completion 
of the test she reported a score of 18 “very hard” Borg RPE (6-20) [29]. 
The CST improved by 50% to 15 stands on reassessment at week five 
and to 20 stands prior to discharge at week ten, yielding a 100% total 
improvement. This resulted in a total change from 15%ile on initial 
evaluation to 75%ile prior to discharge on comparative normative data. 
Discussion
Overall, there is a dearth of published outcome measures for persons 
with DM2. This case highlights the utility of the HiMAT and the CST 
as novel and appropriate measures for further investigation in the DM 
population. This case provides an example of how PT intervention 
assisted a person with DM2 and demonstrates improvements in balance 
and function. The results of this case report support the value of PT 
in helping persons with DM2 learn about managing their condition to 
optimize functional mobility and activity participation.
In this case, the HiMAT detected an overall improvement in function 
that persisted across weeks of repeated measurement. J.D.’s ability to 
perform repetitive sit-to-stand was reflected in the 100% change from 
the baseline score. The increase in the HiMAT score on reassessment 
was further supported by her return to prior level of function and 
gym-based exercise and running. The increase in some HiMAT score 
categories and decrease in others could possibly be explained by a 
cumulative effect of muscles fatigue on performance through the test 
item progression, or by a potential training effect. Further inquiry on 
the HiMAT and CST is warranted across neuromuscular populations to 
establish reliability and validity of the tool. Future research and clinical 
trials should consider utilizing the HiMAT and CST as a measure of 
physical function to monitor change in response to intervention.
Critical to this case was continually evaluating the patient’s 
response to treatment using an activity log. Managing the immediate 
effects of DM2 during PT treatment included allowing extra time for 
muscle relaxation between exercise repetitions and limiting exercise 
to a muscle group indicated by cramping and/or onset of tremor. 
Patient education was essential to the patient’s progress to address 
complete muscle relaxation between repetitions to reduce myotonia. 
The integration of developmental postures in the PT treatment plan was 
instrumental in promoting motor learning of the proximal and core 
stabilization muscles in the absence of movement substitutions patterns 
or compensations.  
DM2 is a rare neuromuscular disorder. Persons with DM2 
may benefit from physical therapy treatment to address functional 
impairments such as muscle weakness, pain, stiffness, decreased 
endurance, and activity limitations that are commonly associated 
with the disorder. Furthermore, other clinical features of DM2 
include conductive cardiac disease and progressive cardiomyopathy 
[2,5,7,11,30,31]. The frequency and severity of cardiac involvement in 
DM2 is less than in DM1 [32]. However, the risk for cardiac arrhythmia 
and other complications do exist [32]. Physical therapists should be 
aware of the potential for asymptomatic cardiomyopathy, heart failure, 
and risk for serious cardiac complications when treating persons with 
DM2. Therefore, physician clearance prior to initiating an exercise 
program is imperative and should always be obtained. However, the 
parameters of an optimal cardiorespiratory exercise program are not 
yet fully understood for persons with DM2 and should be a topic of 
future study. 
There are limitations to this case report, including a single-subject 
report. The lack of an objective quantitative measure of muscle strength 
(i.e., handheld dynamometry) was also a limitation in this case report. 
Therefore, the results and interpretation of the responsiveness of the 
HiMAT in this case is cautioned as a possible training effect could 
have impacted the change in performance. Additionally, various 
mechanisms have been found to generate musculoskeletal pain in DM2 
including exercise, temperature, and palpation [32].  Routine physical 
activity may help to control musculoskeletal pain, and this appears to be 
supported in this case [33]. Rehabilitation providers should understand 
Table 2:  HiMAT results at initial examination, re-evaluation, and discharge.
HiMAT item Initial Evaluation Week 4 Re-evaluation Week 8 Re-evaluation
Category Performance Score Performance Score Performance Score
10-m Walk 4.62 s 3 4.13 s 4 4.67 s 3
10-m Walk Backward 10.27 s 2 5.51 s 4 6.02 s 3
10-m Walk on Toes 6.64 s 3 5.13 s 4 6.00 s 3
10-m Walk over Obstacles 6.15 s 2 4.61 s 3 3.92 s 4
10-meter Run 2.32 s 2 1.85 s 3 1.58 s 4
10-m Skip 3.32 s 3 3.01 s 3 3.29 s 3
10-m Hop Forward 5.40 s 2 5.13 s 3 6.31 s 2
Bound- Affected LE 93.1cm 2 100.43cm 2 121.6cm 3
Bound – Less-Affected LE 105.3cm 2 110cm 3 124.7cm 3
Up Stairs- Dependent Reciprocal no rail 5 Reciprocal no rail 5 Reciprocal no rail 5
Up Stairs-Independent 7.66 s 2 6.82 s 3 5.22 s 4
Down Stairs-Dependent Reciprocal no rail 5 Reciprocal no rail 5 Reciprocal no rail 5
Down Stairs- Independent 5.54 s 4 4.43 s 4 3.08 s 4
Total Score  ___/54 37 46 46
High-Level Mobility Assessment Tool1-3, cm – centimeter, m – meter, LE – Lower extremity,  s – seconds
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the potential for symptom exacerbation with resistive exercise in 
persons with neuromuscular disorders. However, currently, it is not yet 
fully known how prescribing resistive exercise can affect the degree to 
which skeletal or cardiac muscle function may be enhanced or further 
impaired in DM2. Similarly, it is not yet fully understood how various 
levels of exercise training may enhance or impair myotonia [30]. 
Therefore, therapists should use caution when implementing a strength 
or cardiorespiratory training program in persons with DM2. 
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Implications for Rehabilitation
•	 The High-level Mobility Assessment Tool can detect change in 
function in DM2.
•	 The 30-second Chair Stand Test can detect improvements in muscle 
strength in DM2.
•	 Improvements in manual muscle testing were noted after physical 
therapy treatment. 
•	 Exercise and physical therapy can promote return to function in a 
person with DM2. 
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